Quick Answer
Adaptive Biotechnologies Corp reported R&D Expense of $93.77 million for fiscal year 2025.
Adaptive Biotechnologies Corp R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $93.77M | -8.9% |
| 2024 | $102.95M | -15.7% |
| 2023 | $122.12M | -13.9% |
| 2022 | $141.76M | -0.4% |
| 2021 | $142.34M | +22.6% |
| 2020 | $116.07M | +64.2% |
| 2019 | $70.70M | +80.6% |
| 2018 | $39.16M | +22.4% |
| 2017 | $32.00M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $23.67M | -2.0% | -1.9% |
| June 30, 2025 | $24.13M | -4.8% | -0.3% |
| March 31, 2025 | $24.20M | -20.0% | +0.2% |
| September 30, 2024 | $24.16M | -15.3% | -4.7% |
| June 30, 2024 | $25.35M | -21.4% | -16.2% |
| March 31, 2024 | $30.25M | -7.2% | +6.0% |
| September 30, 2023 | $28.53M | -20.0% | -11.5% |
| June 30, 2023 | $32.24M | -13.0% | -1.1% |
- Adaptive Biotechnologies Corp showed a decrease of -8.9% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2025 period, Adaptive Biotechnologies Corp’s r&d expense has grown by 193.1% (from $32.00 million to $93.77 million).
- The most recent figure is from Adaptive Biotechnologies Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: